Results

1–10 of 21 results for Faricimab

Faricimab Response is Associated With Intraocular Pressure Lowering in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
Tamara L Lenis, MD, PhD
Annual Meeting Talks
2024
Pigment Epithelial Detachment Outcomes With Faricimab vs Aflibercept in Patients With nAMD: Results From TENAYA/LUCERNE
Aude Ambresin, MD, PD
Annual Meeting Talks
2024
Efficacy, Safety, and Durability of Faricimab in Macular Edema Due to Retinal Vein Occlusion: 72-Week Results From the Phase 3 BALATON and COMINO Trials
Carl J Danzig, MD
Annual Meeting Talks
2024
12-Month Real-World Clinical and Anatomic Outcomes With Faricimab in Patients With Diabetic Macular Edema: The FARETINA-DME Study
Theodore Leng, MD, MS, FASRS
Annual Meeting Talks
2024
Efficacy, Safety, and Durability of Faricimab in Macular Edema Due to Retinal Vein Occlusion:72-Week Results From the Phase 3 BALATON and COMINO Trials
Carl J Danzig, MD
Updates from the Field
2024
Angiopoietin-2 Signaling and Vascular Stability With Faricimab in Diabetic Macular Edema
Karl G. Csaky, MD, PhD
Annual Meeting Talks
2022
Personalized Treatment Interval Dosing Dynamics Over 2 Years in the Phase 3 YOSEMITE and RHINE Trials of Faricimab in Diabetic Macular Edema
John W. Kitchens, MD
Annual Meeting Talks
2022
Efficacy, Durability, and Safety of Faricimab in Diabetic Macular Edema: 2-Year Results of the Phase 3 YOSEMITE and RHINE Trials
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2022
Real World Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study
Carl J Danzig, MD
Annual Meeting Talks
2022
Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2022